FDA Fast-Tracks Psychedelic Therapies for Depression, PTSD, and Alcohol Use Disorder (Copy)
The FDA is accelerating the development of psychedelic therapies for serious mental illnesses by issuing priority review vouchers, approving early-stage trials, and preparing new research guidelines. These efforts target conditions like depression and PTSD, where current treatments are limited. It also approved the first U.S. trial of an ibogaine-derived drug for alcohol use disorder.
The move reflects stronger federal support but also emphasizes stricter scientific standards. Overall, the FDA is speeding up progress while aiming to ensure safety and reliable evidence.
Cindy L. Carter, Ph.D.